Related references
Note: Only part of the references are listed.A multicenter, randomized, double-blind, placebo-controlled, dose-escalation trial assessing safety and efficacy of active site inactivated recombinant factor VIIa in subjects with acute lung injury or acute respiratory distress syndrome
Jean-Louis Vincent et al.
CRITICAL CARE MEDICINE (2009)
Randomized clinical trial of activated protein C for the treatment of acute lung injury
Kathleen D. Liu et al.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE (2008)
PAI-1 inhibits neutrophil efferocytosis
Young-Jun Park et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Drotrecogin alfa (activated) in children with severe sepsis: a multicentre phase III randomised controlled trial
Simon Nadel et al.
LANCET (2007)
Bench to bedside: targeting coagulation and fibrinolysis in acute lung injury
Lorraine B. Ware et al.
AMERICAN JOURNAL OF PHYSIOLOGY-LUNG CELLULAR AND MOLECULAR PHYSIOLOGY (2006)
From evidence to clinical practice: Effective implementation of therapeutic hypothermia to improve patient outcome after cardiac arrest
Mauro Oddo et al.
CRITICAL CARE MEDICINE (2006)
Alveolar plasminogen activator inhibitor-1 predicts ARDS in aspiration pneumonitis
AA El Solh et al.
INTENSIVE CARE MEDICINE (2006)
Expression of angiostatin, integrin αvβ3, and vitronectin in human lungs in sepsis
B Singh et al.
EXPERIMENTAL LUNG RESEARCH (2005)
The kringle domain of urokinase-type plasminogen activator potentiates LPS-induced neutrophil activation through interaction with αvβ3 integrins
SH Kwak et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2005)
Drotrecogin alfa (activated) for adults with severe sepsis and a low risk of death
E Abraham et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Regulation of lipopolysaccharide-induced lung inflammation by plasminogen activator inhibitor-1 through a JNK-mediated pathway
PG Arndt et al.
JOURNAL OF IMMUNOLOGY (2005)
Efficacy and safety of tifacogin (recombinant tissue factor pathway inhibitor) in severe sepsis -: A randomized controlled trial
E Abraham et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2003)
High-dose a randomized antithrombin III in severe sepsis -: A randomized controlled trial
BL Warren et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2001)
Efficacy and safety of recombinant human activated protein C for severe sepsis.
GR Bernard et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
Share Paper
